Subject Index: Australian Prescriber Volumes 17 to current (1994-2013)

ABCDEFGHIJKLMNOPQRSTUVWXYZ

Page: 1 of 24 - Total records found: 279
FirstPrevious12345678910NextLast
abacavir
HIV - Ziagen (New drug) Vol 22 No 5 125-7
lamivudine - zidovudine combination - Trizvir (New combination) Vol 24 No 6 155-8
abatacept
rheumatoid arthritis - Orencia (New drug) Vol 30 No 6 163-7
abciximab
in antiplatelet therapy Vol 19 No 4 98-101
coronary angioplasty - ReoPro (New drug) Vol 19 No 3 81-3
Abilify
see aripiprazole Vol 26 No 5 118-9
abiraterone acetate
Zytiga - metastatic prostate cancer (New drug) Vol 35 No 4 128-35
abnormal laboratory results (see also diagnostic tests)
abnormal haematology results in children Vol 27 No 3 64-6
'Abnormal laboratory results' - book review Vol 25 No 2 28
abnormalities in pregnancy Vol 29 No 2 48-52
adrenocortical function in adults Vol 30 No 6 147-9
allergy testing Vol 25 No 4 91-3
antibodies to cyclic citrullinated peptides in rheumatoid arthritis Vol 29 No 6 162-4
arterial blood gases Vol 33 No 4 124-9
biochemical tests in pregnancy Vol 28 No 4 98-101
bone turnover markers Vol 35 No 5 156-8
dental notes Vol 35 No 5 159
BRCA testing for familial breast cancer Vol 34 No 2 49-51
cardiac markers Vol 26 No 4 88-90
cell markers Vol 30 No 5 128-9
congestive heart failure and B-type natriuretic peptide Vol 26 No 3 64-5
C-reactive protein Vol 30 No 3 74-6
creatinine clearance and renal function Vol 24 No 1 15-7
diagnostic tests and litigation (editorial) Vol 35 No 4 106-7
dental notes Vol 35 No 4 107
drug screens Vol 24 No 4 90-1
fertility testing Vol 25 No 2 38-40
haemostasis disorders Vol 18 No 2 38-41
dental implications Vol 18 No 2 48
HDL cholesterol Vol 17 No 4 99-102
Sheffield tables Vol 21 No 4 98-9
Helicobacter pylori Vol 20 No 4 96-8
hepatitis B Vol 21 No 3 72-5
dental implications Vol 21 No 3 79
hepatitis C Vol 22 No 4 91-4
HFE-related haemochromatosis Vol 34 No 3 73-6
iron deficiency Vol 20 No 3 74-6
multiple myeloma screening Vol 32 No 4 92-4
paediatric biochemical tests Vol 28 No 5 126-9
pitfalls in interpretation Vol 32 No 2 43-6
point-of-care testing Vol 33 No 1 6-9
prostate specific antigen Vol 34 No 6 186-8
cost of tests (letter) Vol 17 No 1 4-5
sensitivity and specificity Vol 25 No 5 107
sexually transmitted infections Vol 30 No 1 8-13
tests for cell-mediated immunity Vol 33 No 3 84-7
thalassaemia screening Vol 24 No 5 120-3
therapeutic drug monitoring Vol 31 No 2 42-4
therapeutic range of digoxin (letter) Vol 31 No 5 115-8
thrombophilia Vol 22 No 3 63-6
thyroid function tests Vol 34 No 1 12-5
tumour markers Vol 35 No 4 125-8
urinary drug screening Vol 36 No 2 62-4
abnormalities, congenital - see birth defects
Aboriginal people
Aboriginal primary health care (book review) Vol 27 No 1 9
access to the Pharmaceutical Benefits Scheme Vol 34 No 2 38-40
cardiovascular disease management Vol 33 No 3 72-5
CARPA Standard Treatment Manual (book review) Vol 27 No 1 8
drug therapy Vol 26 No 5 106-9
medication compliance and Aboriginal children (letter) Vol 26 No 2 27-9
medication management Vol 28 No 5 123-5
subsidised medicines Vol 31 No 4 89
abortion, therapeutic
mifepristone Vol 32 No 6 152-4
mifepristone - Mifepristone Linepharma - termination of pregnancy (New drug) Vol 36 No 1 32-5
ACAM2000
see vaccinia smallpox vaccine Vol 32 No 6 165-171
acamprosate
alcohol dependence Vol 25 No 3 70-3
Campral (New drug) Vol 22 No 6 147-51
acarbose
antidiabetic - Glucobay (New drug) Vol 21 No 2 49-55
drug interactions Vol 24 No 4 83-5
HomeHome Contact usContact us Free subscriptionFree subscription Useful linksUseful links User guideUser guide Legal informationLegal information Privacy noticePrivacy notice Web manager